Fosun Pharma subsidiary licenses autoimmune drug, eyes China market

Shanghai Fosun Pharmaceutical Group (Fosun Pharma) announced that its subsidiary, Fosun Pharma Industrial Development, secured an exclusive license from Arkas for the AC-201 molecule. This agreement grants exclusive rights for research, development, manufacturing, registration, and commercialization of AC-201, an oral small-molecule JAK inhibitor, within Mainland China and Hong Kong and Macau regions, targeting human diseases including autoimmune conditions. AC-201 has completed Phase II clinical trials in China for moderate to severe plaque psoriasis, showing good safety and tolerability. The deal involves an upfront payment of CNY 60 million and up to CNY 96 million in milestone payments, with additional sales royalties.

In other news, Fosun Pharma also announced that two private equity funds it helped establish, Angi Innovation Medical Device Fund and Xuzhou Innovation Medical Device Fund, will be liquidated and deregistered. These funds had not yet commenced investment operations. Additionally, the company disclosed the renewal of a loan for its controlled subsidiary, Fuyun Health. The loan, totaling CNY 15.29 million, provided by Fosun Health, Ningbo Futech, and Fosun High-Tech, will be extended by 12 months to September 4, 2026, with an adjusted annual interest rate of 3.2% from September 5, 2025. This renewal is within the scope of previously approved internal and related party transactions.